Shares of Summit Therapeutics (SMMT) moved higher after its Chief Accounting Officer Bhaskar Anand disclosed the purchase of 26,680 shares at an average price of $18.74, for a total of $499,983. Anand now owns 159,751 shares of Summit. The stock in after-hours trading is up 4% to $19.53.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SMMT:
- Biotech Alert: Searches spiking for these stocks today
- Summit Therapeutics Faces Financial Uncertainty: Potential Impact on Operations and R&D
- Summit Therapeutics Raises $500M in Private Placement
- Summit Therapeutics to sell 26.68M shares at $18.74 in private placement
- Summit Therapeutics price target lowered to $40 from $50 at H.C. Wainwright